VTT and German Bayer Schering Pharma AG start research collaboration
VTT will study the mechanism of action of a new cancer drug for Bayer Schering Pharma AG
VTT has signed a twoyear contract on research collaboration with Bayer Schering Pharma AG regarding the studies on the mode of action of a new cancer drug developed by Bayer Schering Pharma AG. The research will be conducted at VTT by researchers of Medical Biotechnology. The work will utilize the new gene and cell biology methods developed by VTT.
The contract is an important initiative from VTT towards the international
pharmaceutical industry, and is a part of VTT’s objectives in combining
scientific and technology excellence to facilitate drug development processes.
The project strengthens the aims of VTT to develop and market its core
Research in Medical Biotechnology at VTT:
VTT develops and applies novel research methods for drug development and diagnostics. The focus is in identifying primary driver genes and targets of genetic alterations in cancer as well as in finding drug compounds preventing the growth and metastasis of breast and prostate cancer. VTT employs 70 researchers and staff members that work within versatile technology development and drug discovery projects as well as in basic cancer research funded by the European Commission, Tekes, the Finnish Funding Agency for Technology and Innovation, and Academy of Finland. VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for Translational Genomewide Biology.